评估[64Cu]CuCl2在胶质母细胞瘤球体中的诊疗一体化潜力
研究从三种胶质母细胞瘤细胞系(T98G、U373、U87)及一种非肿瘤星形细胞系建立三维球体,评估[64Cu]CuCl2暴露后球体生长、活力和细胞增殖能力的变化,并分析64Cu摄取、铜转运蛋白CTR1表达、肿瘤干细胞样细胞群及活性氧产生。结果显示[64Cu]CuCl2能显著降低球体生长和活力并影响细胞增殖能力,64Cu摄取、肿瘤干细胞样细胞存在及活性氧产生与治疗反应一致,但CTR1表达水平与摄取水平不一致,提示其他机制可能参与64Cu摄取。结论支持[64Cu]CuCl2作为胶质母细胞瘤诊疗一体化药物的潜力。
要点
- [64Cu]CuCl2可显著降低三种胶质母细胞瘤球体的生长和活力,并影响细胞增殖能力。
- 64Cu摄取、肿瘤干细胞样细胞存在及活性氧产生与治疗反应一致。
- CTR1表达水平与64Cu摄取水平不一致,提示其他机制可能参与摄取。
核心结论
- 结果进一步支持[64Cu]CuCl2作为胶质母细胞瘤诊疗一体化药物的潜力,并揭示了可能参与治疗反应的机制。
研究设计与样本
- 体外研究:从三种胶质母细胞瘤细胞系(T98G、U373、U87)及一种非肿瘤星形细胞系建立三维球体,评估[64Cu]CuCl2暴露后的治疗反应并探讨相关机制。
主要发现
- [64Cu]CuCl2能显著降低球体生长和活力,同时影响细胞增殖能力。
- 64Cu摄取、肿瘤干细胞样细胞存在及活性氧产生与治疗反应一致。
- CTR1表达水平与64Cu摄取水平不一致,提示其他机制可能参与64Cu摄取。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma is an extremely aggressive malignant tumor with a very poor prognosis. Due to the increased proliferation rate of glioblastoma, there is the development of hypoxic regions, characterized by an increased concentration of copper (Cu). Considering this, 64Cu has attracted attention as a possible theranostic radionuclide for glioblastoma. In particular, [64Cu]CuCl2 accumulates in glioblastoma, being considered a suitable agent for positron emission tomography. Here, we explore further the theranostic potential of [64Cu]CuCl2, by studying its therapeutic effects in advanced three-dimensional glioblastoma cellular models. First, we established spheroids from three glioblastoma (T98G, U373, and U87) and a non-tumoral astrocytic cell line. Then, we evaluated the therapeutic responses of spheroids to [64Cu]CuCl2 exposure by analyzing spheroids' growth, viability, and cells' proliferative capacity. Afterward, we studied possible mechanisms responsible for the therapeutic outcomes, including the uptake of 64Cu, the expression levels of a copper transporter (CTR1), the presence of a cancer stem cell population, and the production of reactive oxygen species (ROS). RESULTS: Results revealed that [64Cu]CuCl2 is able to significantly reduce spheroids' growth and viability, while also affecting cells' proliferation capacity. The uptake of 64Cu, the presence of cancer stem-like cells and the production of ROS were in accordance with the therapeutic response. However, expression levels of CTR1 were not in agreement with uptake levels, revealing that other mechanisms could be involved in the uptake of 64Cu. CONCLUSIONS: Overall, our results further support [64Cu]CuCl2 potential as a theranostic agent for glioblastoma, unveiling potential mechanisms that could be involved in the therapeutic response.
引用
- Pinto CIG, Branco ADM, Bucar S, et al. Evaluation of the theranostic potential of [64Cu]CuCl2 in glioblastoma spheroids. EJNMMI Res. 2024. PMID: 38453813. doi:10.1186/s13550-024-01084-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。